Document is current

Any future updates will be listed below

757 LBL-042, a novel bispecific antibody, has the potential to improve immune evasion in cancer by targeting not only T but also myeloid suppressive cells

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.0757

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark